E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Efficacy of belimumab to improve subclinical cardiovascular abnormalities using imaging endpoints with cardiac magnetic resonance in patients with systemic lupus erythematosus |
Wirksamkeit von Belimumab zur Verbesserung subklinischer kardiovaskulärer Anomalien anhand bildgebender Endpunkte mit kardialer Magnetresonanz bei Patienten mit systemischem Lupus erythematodes |
|
E.1.1.1 | Medical condition in easily understood language |
Efficacy of belimumab to improve cardiovascular abnormalities in patients with systemic lupus erythematosus |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
•To determine myocardial changes due to diffuse inflammatory involvement measured by T1 and T2 mapping and first pass perfusion imaging under maximal vasodilation in SLE patients with new initiation of belimumab or continued standard-of care therapy at W24 compared to BL |
|
E.2.2 | Secondary objectives of the trial |
Assess. of cardiovasc. risk factors and funct. (deform. and cardiac function (longitudinal strain, left ventricular (LV) volume and mass, ejection fraction, LGE, ECG, aortic stiffness (pulse wave velocity), myocardial triglyeride an creatine content (subgroup of patients) Assess.of cardiovas. risk factors and cardiac biomarkers measured in blood (lipids, triglycerides, VLDL, cholesterine, HDL, LDL, glucose, HbA1c, (apo)lipoproteine levels, hs-troponin T, NT-BNP, hsCRP) Assess. of antiphospholipid profile (lupus anticoagulant, anticardiolipin and anti-beta 2 GPI) Measurement of vital signs Assess. of cardiac echocardiography Determin. of SLE disease activity and damage (SLEDAI 2k, S2k Responder Index-50, SLICC damage index, CRP/ESR, PGA) Incidence of cardiovas. abnormalities PGIC LupusQoL Facit-Fatigue subscale CSSRS Compliance of belimumab/SLE Assess. of treatment changes Safety Parameters Rise in cardiac biomarkers/frequency of worsening of disease Subgroup analysis |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Proton magnetic resonance spectroscopy (1H-MRS) (optional) A subgroup of patients (of the university hospital Düsseldorf) will receive 1H-MRS for the detection of myocardial triglyceride and creatine content. 1H-MRS will be included in the CMR examinations at SCR, V4, V6 and V7. The duration of the CMR will be prolonged for 8 minutes. Study participants should be fasted for 4 hours prior examination. This is an optional assessment, i.e., patients can still participate in the study, if they do not perform this assessment
|
Proton magnetic resonance spectroscopy (1H-MRS) (optional); Included in protocol Version 1.6 (only a subgroup of patients of the university hospital Düsseldorf( |
|
E.3 | Principal inclusion criteria |
1. Established diagnosis of SLE as per American College of Rheumatology revised classification criteria 2. Stable disease (SLEDAI < 6 and no treatment change) over the last 12 weeks 3. Cardiac abnormalities of recovery rate of T1 or T2 relaxation detected in CMR, measured in a midventricular SAX slice conservatively within the septal myocardium defined as follows: a. Native T1 ≥ 4SD: 1.5T 1050ms, 3.0T 1150 ms or b. Native T2 ≥ 4SD : 1.5T 50ms, 3.0T 40 ms 4. If pericarditis is diagnosed: a. colchicine therapy will be started with a maximum of 0,5 mg once daily as indicated 5. If concomitant cortisone treatment: stable dose (≤ 10 mg/day) within the last 2 weeks 6. Patients with a BMI of 18-35 kg/m² 7. Patients aged 18 - 75 years 8. Written informed consent obtained prior to the initiation of any protocol-required procedures by the patient 9. Willingness to comply to study procedures and study protocol
|
|
E.4 | Principal exclusion criteria |
Main exclusion criteria 1. Previous use of belimumab 2. Contraindications for treatment with belimumab (e.g., hypersensitivity to IMP) 3. Use of Rituximab and other B-cell-targeting therapies (e.g., anti-CD20 antibodies) within 12 months before BL 4. Use of Cyclophosphamide within 90 days before BL 5. Concomitant cortisone with dosages >10 mg/day 6. Vaccination with live vaccine within 30 days prior to BL 7. History of malignant neoplasm within the last 5 years except basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years 8. Any other clinically significant abnormal laboratory value in the opinion of the investigator 9. Any intercurrent significant medical or psychiatric illness that the investigator considers would make the candidate unsuitable for the study (e.g. severe depression) 10. Clinically manifest cardiovascular symptoms, e.g.: o Severe congestive heart failure (NYHA III-IV), EF < 35%, AV block, Mobitz type II o Established severe ischaemic heart disease, peripheral arterial disease and/or cerebrovascular disease o History of bypass surgery or triple vessel disease, presence of flow limiting obstructive coronary artery disease, congenital or clinically relevant vavular heart disease 11. Significant IgG deficiency (IgG level < 400 mg/dL) 12. IgA deficiency (IgA level < 10 mg/dL) 13. Renal disease with a current estimated GFR < 30 mL/min/1.73 m² 14. Patients with a history of a major organ transplant (i.e., heart, lung, kidney, liver) or hematopoetic stem cell/marrow transplant within the last 5 years 15. Patients with lupus nephritis 16.Evidence of significant uncontrolled concomitant diseases or serious and/or uncontrolled diseases that are likely to interfere with the evaluation of the patient’s safety and of the study outcome 17. History of primary immunodeficiency 18. Current suppressive therapy for a chronic infection (such as tuberculosis, pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster and atypical mycobacteria), hospitalization for treatment of infection within 60 days before SCR, or use of parenteral (IV or IM) antiobiotics (anti-bacterial, antiviral, anti-fungal, or anti-parasitic agents) within 60 days before SCR 19. History of an anaphylactic reaction to parenteral administration of contrast agents, human or murine proteins or monoclonal antibodies 20. History of or active status of Hepatitis (positive testing for HBsAG/HBcAb/Hepatitis C) and/or positive HIV test 21. Evidence of serious suicide risk including any history of suicidal behaviour in the last 6 months and/or any suicidal ideation in the last 2 months or who in the investigator's judgment poses a significant suicide risk 22. Contraindications to contrast material-enhanced CV magnetic resonance (MR) imaging 23. Current alcohol, drug or chemical abuse or dependence or within 1 year before SCR 24. Males or females of reproductive potential as well as menopausal women not willing to use effective contraception for the duration of the study period (defined as PEARL index <1 - e.g. contraceptive pill, IUD, or true sexual abstinence within the last 4 weeks and the study period, bilateral tubal occlusion or male partner with vasectomy; also see chapter 7.4.4 for guidance) 25. Current participation in another interventional clinical trial or participation within the last 3 months for non-biological IMPs and 12 months for biologic IMPs 26. Lupus of the central nervous system 27. Severe hyponatremia (sodium > 155 mmol/l) 28. Moderate neutropenia: neutrophil count less than 1000µl (or defined as leukocytes less than 2000/µl if blood count is not further examined) 29. Current severe infection (e.g. sepsis, pneumonia) 30. Progressive multifocal leucencephalopathy
For female subjects only: 31. Positive pregnancy test at screening examination 32. Pregnant or lactating women |
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Treatment group difference in change in diffuse myocardial inflammation and myocardial blood flow using T1 and T2 mapping and first pass perfusion imaging at W24 compared to baseline |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
•Primary endpoint will be analysed after 24 weeks (Visit 4) |
|
E.5.2 | Secondary end point(s) |
Secondary endpoints will be analysed at all available visits for both treatment groups. For all continuous endpoints, “changes” refer to the difference between the visit measurement and baseline (absolute and in %): •T1 and T2 values and change thereof compared to BL •Longitudinal strain and change thereof compared to BL •Left ventricular (LV) volume and mass and change thereof compared to BL •Ejection fraction and change thereof compared to BL •Late gadolinium enhancement (LGE) and change thereof compared to BL •Pulse wave velocity and change thereof compared to BL •Changes in values in cardiac echocardiography and ECG •Presence and extent of coronary artery calcification and soft plaques •SLEDAI-2k score and change to BL •Sledai-2k responder index-50 (S2k RI-50) and change to BL •Proportion of patients with partial and complete recovery according to Sledai-2k and S2k RI-50 •SLICC score and change to BL •Proportion of patients that fulfil SLICC criteria (The SLICC criteria for SLE classification requires: 1) Fulfillment of at least four criteria, with at least one clinical criterion AND one immunologic criterion OR 2) Lupus nephritis as the sole clinical criterion in the presence of ANA or anti-dsDNA antibodies) •Physicians global assessment (PGA) and change to BL •Changes in cardiovascular risk factors and cardiac biomarkers in blood (lipids, triglycerides, VLDL, cholesterine, HDL, LDL, glucose, HbA1c, (apo)lipoproteine levels, hs-troponin T, NT-BNP) and CRP (+hsCRP) and ESR compared to BL •Blood pressure, heart rate and change thereof compared to BL •Patient global impression of change (PGIC/SGIC) score •Lupus Quality of Life score and change to BL •Facit-Fatigue subscale score and change to BL •CSSRS score and change to BL •Oral corticosteroid dose •Benlysta®/ SOC intake (empty syringes/pens) and patient diary information for drug accountability / compliance •Proportion of patients with a treatment change and proportion of patients who switch to rescue arm; reasons for change /switch •Previous SLE therapies for subgroup analyses using primary and other secondary endpoints
Safety Data: •Frequency, seriousness and number of adverse events and adverse events of special interest •Frequency of worsening of disease (defined as a decreased PGA score) and proportion of patients with worsening of disease •Number of cardiovascular events and proportion of patients with at least one event •Incidence of cardiac abnormalities •Rise in cardiac biomarkers
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Statistical analysis will be performed after termination of the study, when the data review process of the data management is completed and all queries have been solveld. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
data base lock, last site closure |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 4 |